Lupus Reveal Gives Investors a Peek at Biogen’s ‘Underappreciated’ Pipeline

With two late-stage programs set to read out in the next 48 months, Biogen is translating its wealth of experience in multiple sclerosis to lupus—developing a pipeline BMO Capital Markets analysts called “thoughtful.”